Related references
Note: Only part of the references are listed.Off-label and approved use of bevacizumab in elderly patients with colon cancer.
A. I. Neugut et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
Safety, Effectiveness, and Costs of Bevacizumab-Based Therapy in Southern Spain: A Real World Experience
Juan F. Marin-Pozo et al.
MEDICINE (2016)
Association of Off-label Drug Use and Adverse Drug Events in an Adult Population
Tewodros Eguale et al.
JAMA INTERNAL MEDICINE (2016)
Crizotinib Therapy for Advanced Lung Adenocarcinoma and a ROS1 Rearrangement: Results From the EUROS1 Cohort
Julien Mazieres et al.
JOURNAL OF CLINICAL ONCOLOGY (2015)
Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial
Christophe Le Tourneau et al.
LANCET ONCOLOGY (2015)
Off-label use of cancer therapies in women diagnosed with breast cancer in the United States
Sophie Hamel et al.
SPRINGERPLUS (2015)
Prevalence of Off-Label Use of Oral Oncolytics at a Community Cancer Center
Joseph A. Kalis et al.
JOURNAL OF ONCOLOGY PRACTICE (2015)
Use of off-label and unlicenced drugs in hospitalised paediatric patients: a systematic review
Joana Magalhes et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2015)
Strategy to address innovative off-label medication use in China: grading management
Hanbin Wu et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Off-label use of anticancer drugs in eastern Switzerland: a population-based prospective cohort study
M. Joerger et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2014)
Prescribing for off-label use and unauthorized medicines in three paediatric wards in Finland, the status before and after the European Union Paediatric Regulation
L. Lindell-Osuagwu et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2014)
Prevalence of Off-Label Use and Spending in 2010 Among Patent-Protected Chemotherapies in a Population-Based Cohort of Medical Oncologists
Rena M. Conti et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Off-Label Use of Cancer Drugs: A Benchmark Is Established
Monika K. Krzyzanowska
JOURNAL OF CLINICAL ONCOLOGY (2013)
Drug Utilization and Off-label Drug Use in Spanish Pediatric Gastroenterology Outpatients
Belen Ruiz-Antoran et al.
JOURNAL OF PEDIATRIC GASTROENTEROLOGY AND NUTRITION (2013)
Adjuvant bevacizumab-containing therapy in triple-negative breast cancer (BEATRICE): primary results of a randomised, phase 3 trial
David Cameron et al.
LANCET ONCOLOGY (2013)
Use of Administrative Data to Identify Off-Label Use of Second-Generation Antipsychotics in a Medicaid Population
Daniel M. Hartung et al.
PSYCHIATRIC SERVICES (2013)
Unsupported off-label chemotherapy in metastatic colon cancer
Jonas A. de Souza et al.
BMC HEALTH SERVICES RESEARCH (2012)
Japanese Regulatory System for Approval of Off-Label Drug Use: Evaluation of Safety and Effectiveness in Literature-Based Applications
Rumiko Shimazawa et al.
CLINICAL THERAPEUTICS (2012)
International variability in the reimbursement of cancer drugs by publically funded drug programs
P. K. Cheema et al.
CURRENT ONCOLOGY (2012)
Off-label use of anti-cancer drugs between clinical practice and research: the Italian experience
Rosa Lerose et al.
EUROPEAN JOURNAL OF CLINICAL PHARMACOLOGY (2012)
Frequency of the off-label use of antibiotics in clinical practice: a systematic review
Giannoula S. Tansarli et al.
EXPERT REVIEW OF ANTI-INFECTIVE THERAPY (2012)
France's New Framework for Regulating Off-Label Drug Use
Joseph Emmerich et al.
NEW ENGLAND JOURNAL OF MEDICINE (2012)
Bevacizumab in Clinical Practice: Prescribing Appropriateness Relative to National Indications and Safety
Martina Bonifazi et al.
ONCOLOGIST (2012)
A multicenter prospective observational study of the conformity of temozolomide prescriptions in France
Patrick Tilleul et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2012)
The impact of a pharmacist as a member of healthcare team on facilitating evidenced-based prescribing of innovative drugs in an Italian oncology department
Pasquale Cioffi et al.
JOURNAL OF ONCOLOGY PHARMACY PRACTICE (2011)
Effect of Dutasteride on the Risk of Prostate Cancer.
Gerald L. Andriole et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Uncertainty in Assessing Value of Oncology Treatments
C. Daniel Mullins et al.
ONCOLOGIST (2010)
Compassionate use of interventions: results of a European Clinical Research Infrastructures Network (ECRIN) survey of ten European countries
Kate Whitfield et al.
TRIALS (2010)
Systematic review: reliability of compendia methods for off-label oncology indications (vol 150, pg 336, 2009)
A. P. Abernethy et al.
ANNALS OF INTERNAL MEDICINE (2009)
Use of 5-α-Reductase Inhibitors for Prostate Cancer Chemoprevention: American Society of Clinical Oncology/American Urological Association 2008 Clinical Practice Guideline
Barnett S. Kramer et al.
JOURNAL OF CLINICAL ONCOLOGY (2009)
Off-label and unlicensed drug prescribing in three paediatric wards in Finland and review of the international literature
L. Lindell-Osuagwu et al.
JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS (2009)
US physician knowledge of the FDA-approved indications and evidence base for commonly prescribed drugs: results of a national survey
Donna T. Chen et al.
PHARMACOEPIDEMIOLOGY AND DRUG SAFETY (2009)
Systematic Review: Reliability of Compendia Methods for Off-Label Oncology Indications
Amy P. Abernethy et al.
ANNALS OF INTERNAL MEDICINE (2009)
Off-label or off-limits?
Mark Ratner et al.
NATURE BIOTECHNOLOGY (2008)
Defining off-label and unlicensed use of medicines for children: Results of a Delphi survey
Antje Neubert et al.
PHARMACOLOGICAL RESEARCH (2008)
Trastuzumab and metastatic breast cancer: Trastuzumab use in Australia - Monitoring the effect of an expensive medicine access program
Sallie-Anne Pearson et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Reimbursement for cancer treatment: Coverage of off-label drug indications
JOURNAL OF CLINICAL ONCOLOGY (2006)
Off-label prescribing among office-based physicians
David C. Radley et al.
ARCHIVES OF INTERNAL MEDICINE (2006)
The Rresearch on Adverse Drug Events and Reports (RADAR) project
CL Bennett et al.
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION (2005)
Share Paper
